CKD
Advertisement
A study examined the association of ankle-brachial index and CKD progression with type 2 diabetes and elevated BMI.
Could a combined nutritional supplementation and exercise training program improve frailty and health outcomes with CKD?
The Freely Filtered Filtrate discusses the top nephrology stories of 2024, including FLOW, cyberattacks, and IgAN trials.
A study examined whether kidney function decline accelerated after COVID-19 versus other respiratory infections.
A study evaluated the effectiveness of spironolactone for reducing adverse cardiovascular outcomes in older adults with CKD.
Researchers studied the efficacy of exercise in improving cognitive function in people with CKD and its potential harm.
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
A study examined MPS-based gene panel testing in patients with unexplained CKD in a real-world context.
Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear.
Using NURTuRE-CKD data, researchers studied kidney outcomes and heterogeneity of risk by primary renal diagnosis.
Researchers summarized findings on dietary interventions to reduce acid load to manage metabolic acidosis in adults with CKD.
The EMPA-KIDNEY trial examined the effects of SGLT2 inhibition on uric acid and gout in patients with CKD.
Researchers studied the association between chronic kidney disease and postoperative complications.
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
A study examined whether urate-lowering therapy (ULT) for gout might help delay progression of chronic kidney disease (CKD).
A study compared hazard of progression to ESRD in patients with severe CKD who had partial or radical nephrectomy.
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.